Navigation Links
Valeant Pharmaceuticals Announces Private Exchange Offer
Date:3/29/2013

MONTREAL, March 29, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary Valeant Pharmaceuticals International (the "Company") intends to commence an offer to exchange (the "Exchange Offer") any and all of its outstanding $500 million aggregate principal amount of 6.375% Senior Notes due 2020 (the "Existing Notes") for up to an additional $500 million aggregate principal amount of its 6.375% Senior Notes due 2020 (the "Exchange Notes") issued pursuant to the indenture, dated as of October 4, 2012 (the "Date of Issuance"), as supplemented, among the Company, Valeant Pharmaceuticals International, Inc. (the "Parent"), the guarantors named therein and The Bank of New York Mellon Trust Company, as trustee.

The Exchange Notes will be guaranteed by same guarantors of the Existing Notes, which are the Parent and each of the Parent's subsidiaries (other than the Company) that is a guarantor of the Parent's senior secured credit facilities. The form and terms of the Exchange Notes will be substantially identical to the form and terms of the Existing Notes.  The Company is conducting this Exchange Offer in order to satisfy its obligations under the indenture governing the Existing Notes with the anticipated result being that some or all of such notes will be part of a single series of notes under one indenture using a single CUSIP number.

Upon the terms and subject to the conditions of the Exchange Offer, for each $1,000 principal amount of Existing Notes validly tendered, and not withdrawn, in the Exchange Offer for the Existing Notes, eligible holders will receive $1,000 principal amount of Exchange Notes.

The Exchange Offer will expire at 5:00 p.m., New York City time, on April 26, 2013, unless extended or earlier terminated by t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 Research and Markets ( ... "Global POC Diagnostics Market 2015-2019" report to their ... Global POC Diagnostics market to grow at a CAGR ... POC diagnostics are IVD devices and tools used ... setting. The use of these devices helps in the ...
(Date:3/3/2015)... 2015  Columbia Laboratories, Inc. (Nasdaq: CBRX ... a specialty pharmaceutical company focused on pharmaceuticals for women,s ... 27th Annual ROTH Conference, which will take place from ... Dana Point, California . Management,s presentation will ... Pacific Time (12:00 p.m. Eastern Time) in the Promenade ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of the "Global Ultrasound ... , The Global Ultrasound ... 5.79% over the period 2014-2019 Ultrasound ... sound waves. Ultrasound systems are extensively used by ...
Breaking Medicine Technology:Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Global Ultrasound Equipment Market 2015-2019: Rise in Number of MI Diagnostic Procedures with GE Healthcare, Phillips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2
... and Safety of ,First Generation, Antisense, BERKELEY ... GNTA ) announced the presentation of new data ... can be safely administered in high doses by ... presented by Dr. Anthony Tolcher, Director,of Clinical Research, ...
... Improvement in Hemodynamics and Delay Disease Progression -, ... Inc.,today announced positive results from two trials demonstrating ... a combination therapy,for the treatment of pulmonary arterial ... when given in combination with sildenafil,is well-tolerated and ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:3/3/2015)... York, NY (PRWEB) March 03, 2015 ... that allege a metal-on-metal version of the artificial ... debilitating complications continue to move forward in the ... Northern District of Texas. According to the most ... on March 2, 2015, 7,350 Pinnacle hip replacement ...
(Date:3/3/2015)... The number of couples experiencing infertility ... 15%. This increases to 50% by the time a ... Yuzpe AA, et al. Estimating the prevalence of infertility ... Hitkari, a reproductive endocrinologist and co-director at Olive Fertility ... clinical director and founder of Acubalance Wellness Centre will ...
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Splashtop ... collaboration, announces Mirroring360 is now available for Epson® MoverioTM ... from the Moverio Apps Market , iPod, iPhone, ... device experience to the Epson Moverio smart glasses using ... models. , The Epson smart glasses have ...
(Date:3/3/2015)... 03, 2015 OncLive® and Indiana ... joined forces to share news about the center’s ... collaboration is part of OncLive’s Strategic Alliance Partnership ... editorial and marketing teams will partner with the ... cancer center, to highlight accomplishments. They include the ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Growing Pinnacle Hip Litigation 4Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 2Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 3Health News:New Treatment Approach Helps Boost Chance of Pregnancy; Information Seminar at Olive Fertility Center 4Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 2Health News:Splashtop’s Mirroring360 Now Available for Epson® MoverioTM BT-200 Smart Glasses, Enabling Viewing of iOS Apps and Content on Glasses 3Health News:IU Simon Cancer Center Teams with OncLive® in Strategic Alliance Partnership 2Health News:IU Simon Cancer Center Teams with OncLive® in Strategic Alliance Partnership 3
... , TUESDAY, March 29 (HealthDay News) -- Some young ... adjust better than others, a new survey finds. ... their children, aged 11 to 16, who had a ... adolescents, social and psychological adjustment included having negative social ...
... California,s aging lesbian, gay and bisexual population are more likely ... with the challenges of living alone in far higher numbers ... the UCLA Center for Health Policy Research. ... between the ages of 50 and 70 are living alone, ...
... 2011) Patients suffering from dystonia, an uncommon yet potentially ... brain stimulation therapy sooner rather than later, according to an ... Journal of Neurology. "Our data suggest that ... expect a better general outcome than those with longer disease ...
... WHAT & WHY:,The updated agenda for the ... is now available at: http://www.pcioutcomes.com/conference/agenda.html . ... clinical and experimental breakthroughs in the percutaneous ... data on current and second-generation drug-eluting stent ...
... Mothers who were maltreated as children have increased risk ... findings, by researchers at the University of Washington, are ... the health of offspring. The study also finds ... pregnancy contribute to low birth weight, which is linked ...
... Spanish researchers have found that liver transplant recipients who ... (SRM) than patients who keep smoking. In fact, SRMs ... was associated with a higher risk of malignancy in ... issue of Liver Transplantation , a journal of ...
Cached Medicine News:Health News:Older lesbians, gays have higher rates of chronic disease, mental distress, isolation 2Health News:Older lesbians, gays have higher rates of chronic disease, mental distress, isolation 3Health News:For potentially crippling dystonia, earlier deep brain therapy gets better, quicker results 2Health News:For potentially crippling dystonia, earlier deep brain therapy gets better, quicker results 3Health News:Mothers abused during childhood at risk for having low birth weight babies 2Health News:Smoking in combination with immunosuppression poses greater risk for transplant-related carcinoma 2
... series SV stereomicroscopes are of ... to their mature modular design ... job in hand. This is ... demanding routine applications will appreciate, ...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces...
Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
Medicine Products: